Charles River Laboratories International (CRL) Depreciation & Amortization (CF) (2009 - 2025)

Charles River Laboratories International (CRL) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $78.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Depreciation & Amortization (CF) fell 23.34% year-over-year to $78.3 million; the TTM figure through Dec 2025 stood at $403.3 million (up 11.49% YoY), while the FY2025 annual figure was $403.3 million, up 11.49% from the prior year.
• Depreciation & Amortization (CF) came in at $78.3 million for Q4 2025 at Charles River Laboratories International, down from $85.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $120.4 million in Q1 2025, with the low at $61.5 million in Q1 2021.
• Average Depreciation & Amortization (CF) over 5 years is $82.4 million, with a median of $78.0 million recorded in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 41.01% in 2025 against a maximum downside of 23.34% in 2025.
• Year by year, Depreciation & Amortization (CF) stood at $67.2 million in 2021, then gained by 15.32% to $77.5 million in 2022, then gained by 3.83% to $80.5 million in 2023, then gained by 26.82% to $102.1 million in 2024, then fell by 23.34% to $78.3 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $78.3 million, $85.2 million, and $119.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.